Maria Grazia Daidone

List of Publications by Year
in descending order

236	16,194	24978 57	18075 120
papers	citations	h-index	g-index

241	241	241	24380
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Isolation and In vitro Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties. Cancer Research, 2005, 65, 5506-5511.	0.4	1,650
2	Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. New England Journal of Medicine, 2008, 359, 1995-2004.	13.9	1,148
3	The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells. Cell, 2011, 147, 759-772.	13.5	1,115
4	Human Bone Marrowâ€“Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term‹i›In vitro‹/i›Culture and Do Not Exhibit Telomere Maintenance Mechanisms. Cancer Research, 2007, 67, 9142-9149.	0.4	649
5	A MicroRNA Targeting Dicer for Metastasis Control. Cell, 2010, 141, 1195-1207.	13.5	619
6	The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1994, 86, 499-504.	3.0	423
7	miR-205 Exerts Tumor-Suppressive Functions in Human Prostate through Down-regulation of Protein Kinase CÎµ. Cancer Research, 2009, 69, 2287-2295.	0.4	334
8	Rational design of shepherdin, a novel anticancer agent. Cancer Cell, 2005, 7, 457-468.	7.7	311
9	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics, 2008, 9, 239.	1.2	300
10	Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cellular and Molecular Life Sciences, 2002, 59, 1406-1412.	2.4	246
11	Survivin as a target for new anticancer interventions. Journal of Cellular and Molecular Medicine, 2005, 9, 360-372.	1.6	227
12	p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1993, 85, 965-970.	3.0	226
13	30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ: British Medical Journal, 2005, 330, 217.	2.4	224
14	Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer, 1985, 56, 1982-1987.	2.0	207
15	Challenges in Using Circulating miRNAs as Cancer Biomarkers. BioMed Research International, 2015, 2015, 1-10.	0.9	202
16	Different Genetic Features Associated with Colon and Rectal Carcinogenesis. Clinical Cancer Research, 2004, 10, 4015-4021.	3.2	191
17	miR-21: an oncomir on strike in prostate cancer. Molecular Cancer, 2010, 9, 12.	7.9	189
18	A Randomized Trial Comparing Axillary Dissection to No Axillary Dissection in Older Patients With T1N0 Breast Cancer. Annals of Surgery, 2005, 242, 1-6.	2.1	181

#	Article	IF	Citations
19	Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resistance Updates, 2002, 5, 65-72.	6.5	177
20	Association between [18 F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1429-1434.	3.3	161
21	Axillary Dissection Versus No Axillary Dissection in Elderly Patients with Breast Cancer and No Palpable Axillary Nodes: Results After 15 Years of Follow-Up. Annals of Surgical Oncology, 2011, 18, 125-133.	0.7	141
22	Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Research and Treatment, 1986, 7, 161-169.	1.1	138
23	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncology, The, 2012, 13, 810-816.	5.1	130
24	Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer, 1979, 44, 665-670.	2.0	126
25	Breast cancer stem cells: An overview. European Journal of Cancer, 2006, 42, 1219-1224.	1.3	126
26	PIK3CAcancer mutations display gender and tissue specificity patterns. Human Mutation, 2008, 29, 284-288.	1.1	120
27	Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression. Seminars in Cancer Biology, 2015, 35, 3-10.	4.3	120
28	Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Critical Reviews in Oncology/Hematology, 2003, 45, 313-325.	2.0	119
29	Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene, 2008, 27, 2148-2158.	2.6	116
30	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. Cancer Research, 2006, 66, 8918-8924.	0.4	115
31	Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 927-930.	3.0	110
32	Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle, 2013, 12, 1679-1687.	1.3	109
33	A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Critical Reviews in Oncology/Hematology, 2013, 88, 187-197.	2.0	106
34	Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget, 2015, 6, 9627-9642.	0.8	103
35	Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the anti-proliferative activity on a breast-cancer cell line. , 1999, 81, 411-416.		98
36	Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene, 2004, 23, 386-394.	2.6	92

#	Article	IF	Citations
37	Expression of p53, Glutathione S -Transferase-Â, and Bcl-2 Proteins and Benefit From Adjuvant Radiotherapy in Breast Cancer. Journal of the National Cancer Institute, 1997, 89, 639-645.	3.0	91
38	Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. International Journal of Cancer, 1991, 48, 529-532.	2.3	90
39	Radiosensitization of Human Melanoma Cells by Ribozyme-Mediated Inhibition of Survivin Expression. Journal of Investigative Dermatology, 2003, 120, 648-654.	0.3	90
40	Cell kinetics as a prognostic indicator in node-negative breast cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 1165-1171.	0.9	88
41	Small-Molecule Targeting of Heat Shock Protein 90 Chaperone Function:Â Rational Identification of a New Anticancer Lead. Journal of Medicinal Chemistry, 2006, 49, 7721-7730.	2.9	88
42	Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Research and Treatment, 2011, 127, 601-610.	1.1	88
43	Inhibition of telomerase activity by a cell-penetrating peptide nucleic acid construct in human melanoma cells. FEBS Letters, 2000, 473, 241-248.	1.3	82
44	Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer, 2009, 9, 409.	1.1	81
45	Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. European Journal of Cancer, 2005, 41, 624-634.	1.3	80
46	Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells. Journal of Investigative Dermatology, 2010, 130, 1877-1886.	0.3	77
47	Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene, 2004, 23, 8171-8183.	2.6	75
48	Cloning and characterization of a senescence inducing and class II tumor suppressor gene in ovarian carcinoma at chromosome region 6q27. Oncogene, 2001, 20, 980-988.	2.6	73
49	Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Molecular Cancer Therapeutics, 2006, 5, 179-186.	1.9	73
50	Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. Journal of Clinical Investigation, 2002, 109, 285-286.	3.9	73
51	Clinical studies of Bcl-2 and treatment benefit in breast cancer patients.. Endocrine-Related Cancer, 1999, 6, 61-68.	1.6	69
52	Inhibition of Telomerase Activity by a Hammerhead Ribozyme Targeting the RNA Component of Telomerase in Human Melanoma Cells. Journal of Investigative Dermatology, 2000, 114, 259-267.	0.3	68
53	Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Proliferation, 2000, 33, 139-146.	2.4	66
54	A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT. Oncogene, 2009, 28, 3765-3774.	2.6	64

#	Article	IF	Citations
55	Expression of P-glycoprotein and in vitro or in vivo resistance to doxorubicin and cisplatin in breast and ovarian cancers. European Journal of Cancer, 1994, 30, 1002-1007.	1.3	63
56	Cell proliferation in 3,800 node-negative breast cancers: Concistency over time of biological and clinical information provided by3H-Thymidine labelling index. International Journal of Cancer, 1997, 74, 122-127.	2.3	61
57	Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma. Clinical Cancer Research, 2008, 14, 4134-4140.	3.2	61
58	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	0.9	61
59	miR-342 Regulates BRCA1 Expression through Modulation of ID4 in Breast Cancer. PLoS ONE, 2014, 9, e87039.	1.1	59
60	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Clinical Cancer Research, 2016, 22, 337-345.	3.2	58
61	Polyurethane foam scaffold as in vitro model for breast cancer bone metastasis. Acta Biomaterialia, 2017, 63, 306-316.	4.1	58
62	Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. British Journal of Cancer, 2002, 87, 1105-1111.	2.9	57
63	Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis, 2004, 25, 1129-1136.	1.3	57
64	Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis, 2002, 23, 735-740.	1.3	55
65	Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit of human telomerase. Cancer Research, 2003, 63, 3490-4.	0.4	55
66	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Annals of Oncology, 2014, 25, 352-357.	0.6	53
67	Metabolic Footprints and Molecular Subtypes in Breast Cancer. Disease Markers, 2017, 2017, 1-19.	0.6	52
68	Comparison of Microarray Platforms for Measuring Differential MicroRNA Expression in Paired Normal/Cancer Colon Tissues. PLoS ONE, 2012, 7, e45105.	1.1	52
69	Autophagy acts as a safeguard mechanism against G-quadruplex ligand-mediated DNA damage. Autophagy, 2012, 8, 1185-1196.	4.3	51
70	Implications of stemness-related signaling pathways in breast cancer response to therapy. Seminars in Cancer Biology, 2015, 31, 43-51.	4.3	51
71	Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. Journal of Clinical Investigation, 2002, 109, 285-286.	3.9	51
72	Biomolecular prognostic factors in breast cancer. Current Opinion in Obstetrics and Gynecology, 2004, 16, 49-55.	0.9	50

#	Article	IF	Citations
73	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor Î² (TGFÎ²) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Investigational New Drugs, 2014, 32, 555-560.	1.2	50
74	Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. International Journal of Cancer, 1999, 84, 580-586.	2.3	49
75	Time-Dependent Relevance of Steroid Receptors in Breast Cancer. Journal of Clinical Oncology, 2000, 18, 2702-2709.	0.8	47
76	Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. British Journal of Cancer, 2009, 100, 739-746.	2.9	47
77	A lipemia-independent NanoDrop^{Â®}-based score to identify hemolysis in plasma and serum samples. Bioanalysis, 2014, 6, 1215-1226.	0.6	47
78	How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case. Seminars in Cancer Biology, 2017, 44, 106-116.	4.3	47
79	Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochemical Pharmacology, 2007, 73, 1703-1714.	2.0	45
80	Changes in biological markers after primary chemotherapy for breast cancers. International Journal of Cancer, 1995, 61, 301-305.	2.3	44
81	Effects of Warm Ischemic Time on Gene Expression Profiling in Colorectal Cancer Tissues and Normal Mucosa. PLoS ONE, 2013, 8, e53406.	1.1	44
82	Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Research and Treatment, 1981, 1, 253-262.	1.1	43
83	Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines. International Journal of Cancer, 2001, 91, 654-657.	2.3	43
84	Inhibition of telomerase activity by geldanamycin and 17-allylamino, 17-demethoxygeldanamycin in human melanoma cells. Carcinogenesis, 2003, 24, 851-859.	1.3	43
85	By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. Oncotarget, 2015, 6, 2315-2330.	0.8	43
86	Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. Clinical Cancer Research, 2019, 25, 3887-3895.	3.2	42
87	Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines. Biochemical Pharmacology, 2007, 73, 773-781.	2.0	40
88	miR-30e* is an independent subtype-specific prognostic marker in breast cancer. British Journal of Cancer, 2015, 113, 290-298.	2.9	40
89	Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells. European Journal of Cancer, 2002, 38, 1792-1801.	1.3	39
90	Novel Immunofluorescence Protocol for Multimarker Assessment of Putative Disseminating Breast Cancer Stem Cells. Applied Immunohistochemistry and Molecular Morphology, 2011, 19, 33-40.	0.6	39

#	Article	IF	Citations
91	Subtypeâ€dependent prognostic relevance of an interferonâ€induced pathway metagene in nodeâ€negative breast cancer. Molecular Oncology, 2014, 8, 1278-1289.	2.1	39
92	Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. European Journal of Cancer, 2001, 37, 1953-1962.	1.3	38
93	Possible Regulation of Telomerase Activity by Transcription and Alternative Splicing of Telomerase Reverse Transcriptase in Human Melanoma. Journal of Investigative Dermatology, 2001, 116, 867-873.	0.3	37
94	Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Investigational New Drugs, 2004, 22, 207-217.	1.2	37
95	Osteopontin, E-cadherin, and Î²-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer, 2016, 19, 412-420.	2.7	37
96	Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma. Analytical Cellular Pathology, 2007, 29, 453-466.	0.7	35
97	The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. , 1998, 82, 159-167.		34
98	Expression of Phosphatidylethanolamine N-Methyltransferase in Human Hepatocellular Carcinomas. Oncology, 2003, 65, 152-158.	0.9	34
99	Lack of Telomerase Activity in Lung Carcinoids Is Dependent on Human Telomerase Reverse Transcriptase Transcription and Alternative Splicing and Is Associated with Long Telomeres. Clinical Cancer Research, 2005, 11, 2832-2839.	3.2	33
100	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory,RAS-BRAFwild-type colorectal cancer receiving cetuximab or panitumumab. International Journal of Cancer, 2015, 137, 1467-1474.	2.3	33
101	Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine. Cancers, 2019, 11, 1152.	1.7	33
102	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. International Journal of Molecular Sciences, 2020, 21, 1386.	1.8	33
103	Estimation of differential in vitro sensitivity of non-hodgkin lymphomas to anticancer drugs. European Journal of Cancer, 1981, 17, 217-226.	1.0	32
104	Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. Journal of Pathology, 2002, 198, 37-46.	2.1	32
105	Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens. Cellular and Molecular Life Sciences, 2004, 61, 76-82.	2.4	32
106	Response of a comprehensive cancer center to the COVID-19 pandemic: the experience of the Fondazione IRCCSâ€“Istituto Nazionale dei Tumori di Milano. Tumori, 2020, 106, 193-202.	0.6	32
107	Molecular portrait of breast cancer in <scp>C</scp>hina reveals comprehensive transcriptomic likeness to <scp>C</scp>aucasian breast cancer and low prevalence of luminal A subtype. Cancer Medicine, 2015, 4, 1016-1030.	1.3	31
108	Circulating Biomarkers for Prediction of Treatment Response. Journal of the National Cancer Institute Monographs, 2015, 2015, 60-63.	0.9	31

#	Article	IF	Citations
109	Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. British Journal of Cancer, 2001, 84, 651-658.	2.9	30
110	Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer, 2010, 10, 254.	1.1	30
111	Differential expression of telomerase activity in neuroendocrine lung tumours: correlation with gene product immunophenotyping. Journal of Pathology, 2003, 201, 127-133.	2.1	29
112	YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation. International Journal of Cancer, 2015, 136, 299-309.	2.3	29
113	Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. , 1998, 79, 619-623.		28
114	Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. European Journal of Cancer, 2000, 36, 2137-2145.	1.3	28
115	Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. British Journal of Cancer, 2001, 85, 795-797.	2.9	28
116	Activity of a trinuclear platinum complex in human ovarian cancer cell lines sensitive and resistant to cisplatin: cytotoxicity and induction and gene-specific repair of DNA lesions. British Journal of Cancer, 2001, 84, 1387-1390.	2.9	27
117	Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: interference with cell cycle progression and induction of apoptosis. European Journal of Cancer, 2001, 37, 649-659.	1.3	27
118	Prognosis in node-negative primary breast cancer: a neural network analysis of risk profiles using routinely assessed factors. Annals of Oncology, 2003, 14, 1484-1493.	0.6	26
119	Reproducibility of a Semiquantitative Measurement of Circulating DNA in Plasma From Neoplastic Patients. Journal of Clinical Oncology, 2005, 23, 3163-3164.	0.8	26
120	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. International Journal of Biological Markers, 2015, 30, 429-433.	0.7	26
121	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. Cancers, 2021, 13, 2356.	1.7	26
122	Cell Kinetics of Solid Tumors with Time and Its Clinical Implication. Tumori, 1989, 75, 367-372.	0.6	25
123	Changes in cell kinetics induced by primary chemotherapy in breast cancer. International Journal of Cancer, 1991, 47, 380-383.	2.3	25
124	Telomerase Activity in Benign and Malignant Breast Lesions: a Pilot Prospective Study on Fine-Needle Aspirates. Journal of the National Cancer Institute, 1998, 90, 537-539.	3.0	25
125	Selective modulation of ER-? by estradiol and xenoestrogens in human breast cancer cell lines. Cellular and Molecular Life Sciences, 2003, 60, 567-576.	2.4	25
126	Prospective evaluation of estrogen receptor-Î² in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. Endocrine-Related Cancer, 2004, 11, 761-770.	1.6	25

#	Article	IF	Citations
127	High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. British Journal of Cancer, 2008, 98, 1467-1474.	2.9	25
128	Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to Progression. International Journal of Molecular Sciences, 2020, 21, 1475.	1.8	25
129	Reliability of anin vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer, 1985, 56, 450-456.	2.0	24
130	Ribozyme-mediated inhibition of PKC? sensitizes androgen-independent human prostate cancer cells to cisplatin-induced apoptosis. Prostate, 2003, 54, 133-143.	1.2	24
131	Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Proliferation, 2007, 40, 905-920.	2.4	24
132	p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy. Breast, 2015, 24, 294-297.	0.9	24
133	Cell Kinetics: A prognostic marker in epithelial ovarian cancer. Gynecologic Oncology, 1989, 35, 15-19.	0.6	23
134	Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. International Journal of Cancer, 2000, 87, 405-411.	2.3	23
135	Feasibility of circulating miRNA microarray analysis from archival plasma samples. Analytical Biochemistry, 2013, 437, 123-125.	1.1	23
136	Immunohistochemical Detection of p53 in Clinical Breast Cancers: a Look at Methodologic Approaches. Journal of the National Cancer Institute, 1995, 87, 1020-1020.	3.0	22
137	Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro-Oncology, 2012, 14, 736-744.	0.6	21
138	A trans-platinum(II) complex induces apoptosis in cancer stem cells of breast cancer. Bioorganic and Medicinal Chemistry, 2017, 25, 269-276.	1.4	21
139	The Detection and Morphological Analysis of Circulating Tumor and Host Cells in Breast Cancer Xenograft Models. Cells, 2019, 8, 683.	1.8	21
140	Measuring MicroRNA Expression Levels in Oncology: from Samples to Data Analysis. Critical Reviews in Oncogenesis, 2013, 18, 273-287.	0.2	21
141	Estrogen Receptor-Beta Expression in Hereditary Breast Cancer. Journal of Clinical Oncology, 2002, 20, 3752-3753.	0.8	20
142	Cell kinetics and in Vitro chemosensitivity as a tool for improved management of patients. European Journal of Cancer & Clinical Oncology, 1985, 21, 371-378.	0.9	19
143	Involvement of bcl-2 and p21waf1 proteins in response of human breast cancer cell clones to Tomudex. British Journal of Cancer, 1999, 81, 252-260.	2.9	19
144	A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia, 2006, 20, 785-792.	3.3	19

#	Article	IF	Citations
145	AF1q: A Novel Mediator of Basal and 4-HPR-Induced Apoptosis in Ovarian Cancer Cells. PLoS ONE, 2012, 7, e39968.	1.1	19
146	Gene Expression Profiling of Circulating Tumor Cells in Breast Cancer. Clinical Chemistry, 2015, 61, 278-289.	1.5	19
147	Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen. British Journal of Cancer, 2003, 89, 268-270.	2.9	18
148	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers, 2019, 11, 980.	1.7	18
149	Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. International Journal of Cell Cloning, 1989, 7, 385-394.	1.6	17
150	3H-Thymidine labeling index, hormone receptors, and ploidy in breast cancers from elderly patients. Breast Cancer Research and Treatment, 1991, 20, 19-24.	1.1	17
151	A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. International Journal of Cancer, 2020, 146, 3495-3503.	2.3	17
152	int-2 Oncogene amplification and prognosis in node-negative breast carcinoma. , 1997, 74, 620-624.		16
153	Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocrine-Related Cancer, 2008, 15, 439-449.	1.6	16
154	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. British Journal of Cancer, 2014, 110, 26-33.	2.9	16
155	Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. BMC Bioinformatics, 2015, 16, 388.	1.2	16
156	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	3.2	16
157	Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. Cancers, 2019, 11, 1753.	1.7	16
158	Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls. European Journal of Cancer, 2004, 40, 2613-2622.	1.3	15
159	Telomere maintenance in wilms tumors: First evidence for the presence of alternative lengthening of telomeres mechanism. Genes Chromosomes and Cancer, 2011, 50, 823-829.	1.5	15
160	Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma. Oncotarget, 2016, 7, 58903-58914.	0.8	15
161	Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients. Journal of Experimental and Clinical Cancer Research, 2022, 41, 78.	3.5	15
162	The effect of formulation and concentration of cholesteryl butyrate solid lipid nanospheres (SLN) on NIH-H460 cell proliferation. European Journal of Pharmaceutics and Biopharmaceutics, 2001, 52, 197-202.	2.0	14

#	Article	IF	Citations
163	Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Research and Treatment, 1993, 26, 7-13.	1.1	13
164	Severe hemolytic anemia and skin reaction in a patient treated with imatinib. Annals of Oncology, 2003, 14, 962.	0.6	13
165	Biomolecular features of clinical relevance in breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31, S3-S14.	3.3	13
166	ALTâ€associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. Journal of Pathology, 2008, 214, 410-414.	2.1	13
167	Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. Cancer Letters, 2010, 296, 206-215.	3.2	13
168	Cell cycle dependent oscillatory expression of estrogen receptor-Î± links Pol II elongation to neoplastic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9561-9566.	3.3	13
169	Optimizing sharing of hospital biobank samples. Science Translational Medicine, 2015, 7, 297fs31.	5.8	13
170	Clinical Significance of Early Changes inÂCirculating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma1. Bladder Cancer, 2016, 2, 395-403.	0.2	13
171	Detection of Circulating Tumour Cells in Urothelial Cancers and Clinical Correlations: Comparison of Two Methods. Disease Markers, 2017, 2017, 1-11.	0.6	13
172	Potentials of cell kinetics in the management of patients with ovarian cancers. European Journal of Cancer, 1992, 28, 386-390.	1.3	12
173	Re: Tamoxifen May Be an Effective Treatment for BRCA1-Related Breast Cancer Irrespective of Estrogen Receptor Status. Journal of the National Cancer Institute, 2003, 95, 629-630.	3.0	11
174	MicroRNA co-expression patterns unravel the relevance of extra cellular matrix and immunity in breast cancer. Breast, 2018, 39, 46-52.	0.9	11
175	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. European Journal of Cancer, 2019, 118, 1-9.	1.3	11
176	Use of Formalin-Fixed Paraffin-Embedded Samples for Gene Expression Studies in Breast Cancer Patients. PLoS ONE, 2015, 10, e0123194.	1.1	11
177	Involvement of AF1q/MLLT11 in the progression of ovarian cancer. Oncotarget, 2017, 8, 23246-23264.	0.8	11
178	Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 1851-1852.	3.0	10
179	A Breast Cancer Clinical Registry in An Italian Comprehensive Cancer Center: An Instrument for Descriptive, Clinical, and Experimental Research. Tumori, 2015, 101, 440-446.	0.6	10
180	Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues. Biopreservation and Biobanking, 2016, 14, 480-490.	0.5	10

#	Article	IF	Citations
181	Biobanks and scientists: supply and demand. Journal of Translational Medicine, 2018, 16, 136.	1.8	10
182	Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. Advances in Experimental Medicine and Biology, 2017, 994, 83-103.	0.8	10
183	Accurate Data Processing Improves the Reliability of Affymetrix Gene Expression Profiles from FFPE Samples. PLoS ONE, 2014, 9, e86511.	1.1	10
184	In-depth characterization of breast cancer tumor-promoting cell transcriptome by RNA sequencing and microarrays. Oncotarget, 2016, 7, 976-994.	0.8	10
185	Short-term tissue culture of human breast cancer.Presence of estrogen receptors and 17 Î²-estradiol stimulation of RNA synthesis. Cancer, 1979, 43, 2365-2369.	2.0	9
186	p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours. European Journal of Cancer, 1996, 32, 1388-1393.	1.3	9
187	Integrating Collection of Biospecimens in Clinical Trials: The Approach of the European Organization for Research and Treatment of Cancer. Biopreservation and Biobanking, 2011, 9, 181-186.	0.5	9
188	Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies. Cancers, 2011, 3, 1405-1425.	1.7	9
189	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Review of Proteomics, 2014, 11, 237-249.	1.3	9
190	Lack of Activation of Telomere Maintenance Mechanisms in Human Adipose Stromal Cells Derived from Fatty Portion of Lipoaspirates. Plastic and Reconstructive Surgery, 2015, 135, 114e-123e.	0.7	9
191	Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients. Cancers, 2021, 13, 1409.	1.7	9
192	Cell proliferation markers in human solid tumors: Assessing their impact in clinical oncology. Methods in Cell Biology, 2001, 64, 359-384.	0.5	8
193	Association between CASP8 â€“652 6N Del Polymorphism (rs3834129) and Colorectal Cancer Risk: Results from a Multi-Centric Study. PLoS ONE, 2014, 9, e85538.	1.1	8
194	Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody. Cells, 2020, 9, 2231.	1.8	8
195	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clinical Cancer Research, 2021, 27, 6307-6313.	3.2	8
196	Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index. Cell Proliferation, 1990, 23, 401-408.	2.4	7
197	Biological characterisation of primary and metachronous lesions in breast cancer patients. European Journal of Cancer, 1992, 28, 2006-2010.	1.3	7
198	Combined analysis of ploidy and cell kinetics on fine-needle aspirates from breast tumors. Cancer, 1993, 71, 2522-2527.	2.0	7

#	Article	IF	Citations
199	Comprehensive cancer control-research & development: knowing what we do and doing what we know. Tumori, 2009, 95, 610-622.	0.6	7
200	Stromal Activation by Tumor Cells: An in Vitro Study in Breast Cancer. Microarrays (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td	1.4	7
201	Tissue Polypeptide Antigen as a Putative Indicator of Apoptosis. Clinical Chemistry, 1998, 44, 2002-2003.	1.5	6
202	MicroRNA Detection in Plasma Samples. Journal of Molecular Diagnostics, 2013, 15, 138-139.	1.2	6
203	Prognostic and functional role of subtypeâ€specific tumorâ€“stroma interaction in breast cancer. Molecular Oncology, 2017, 11, 1399-1412.	2.1	6
204	What if the future of HER2â€positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Medicine, 2022, 11, 332-339.	1.3	6
205	In Vitro Activity of Alkylating Agents on Human Tumors as Measured by a Short-term Antimetabolic Assay. Tumori, 1985, 71, 555-561.	0.6	5
206	Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay. Investigational New Drugs, 1987, 5, 245-50.	1.2	5
207	Effect of menstrual phase on cell proliferative rate of breast cancer. Breast Cancer Research and Treatment, 1998, 48, 93-94.	1.1	5
208	P53 Accumulation in Primary Breast Cancer: A Comparison between Immunohistochemistry and a Novel Luminometric Immunoassay. Tumor Biology, 1998, 19, 12-18.	0.8	5
209	Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34+ cells. Angiogenesis, 2013, 16, 707-722.	3.7	5
210	Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors. Frontiers in Pharmacology, 2017, 8, 226.	1.6	5
211	Clusterin: A potential target for improving response to antiestrogens. International Journal of Oncology, 1992, 33, 791.	1.4	4
212	Coexpression of survivin and TERT in soft-tissue sarcoma. Lancet, The, 2002, 360, 877.	6.3	4
213	Fixation Time and Microwave Oven Irradiation Affect Immunocytochemical p53 Detection in Formalin-Fixed Paraffin Sections. Applied Immunohistochemistry & Molecular Morphology, 1998, 6, 140-144.	2.0	4
214	Drug Sensitivity of Different Tumor Lesions from the Same Patient Evaluated by a Short-Term Assay. Tumori, 1988, 74, 137-144.	0.6	3
215	Comparing core needle to surgical biopsies in breast cancer for cell kinetic and ploidy studies. Breast Cancer Research and Treatment, 1991, 19, 33-37.	1.1	3
216	Contribution of ploidy and cell kinetics from fine-needle aspirates for the diagnosis of breast lesions: Study of 606 consecutive cases. Cytometry, 1995, 22, 177-180.	1.8	3

#	Article	IF	Citations
217	Effects of liposome-entrapped annamycin in human breast cancer cells: Interference with cell cycle progression and induction of apoptosis. Journal of Cellular Biochemistry, 2001, 81, 9-22.	1.2	3
218	Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen. Breast Cancer Research and Treatment, 2008, 111, 389-390.	1.1	3
219	Strategies to Translate Preclinical Information to Breast Cancer Patient Benefit. Journal of the National Cancer Institute Monographs, 2011, 2011, 55-59.	0.9	3
220	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. European Journal of Cancer, Supplement, 2012, 10, 120-127.	2.2	3
221	RESPONSE: Re: Limits of Predictive Models Using Microarray Data for Breast Cancer Clinical Treatment Outcome. Journal of the National Cancer Institute, 2005, 97, 1852-1853.	3.0	2
222	Introduction to Cancer Biobanking: Why, Where, How?. Biopreservation and Biobanking, 2011, 9, 139-140.	0.5	2
223	Waterâ€soluble derivatives of 4â€oxoâ€Nâ€(4â€hydroxyphenyl) retinamide: synthesis and biological activity. Chemical Biology and Drug Design, 2016, 88, 608-614.	1.5	2
224	SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region. Cancers, 2021, 13, 1035.	1.7	2
225	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. Journal of Clinical Oncology, 2013, 31, 1014-1014.	0.8	2
226	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. JCO Precision Oncology, 2022, 6, e2100472.	1.5	2
227	Report of the EORTC Laboratory Research Division (LDR) Meeting. Breast Care, 2009, 4, 273-274.	0.8	1
228	Concluding Remarks: â€œBiobanking for Cancer Research: Rules and Roles,â€•November 2010, Bari, Italy. Biopreservation and Biobanking, 2011, 9, 195-196.	0.5	1
229	Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. Breast, 2016, 27, 187-188.	0.9	1
230	Workflow for Circulating miRNA Identification and Development in Cancer Research: Methodological Considerations. , 2018, , 103-117.		1
231	Hyaluronic acid as drug delivery for sodium butyrate: Improvement of the antiâ€proliferative activity on a breastâ€cancer cell line. International Journal of Cancer, 1999, 81, 411-416.	2.3	1
232	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. International Journal of Biological Markers, 2013, 28, 24-31.	0.7	0
233	Dissecting Time- from Tumor-Related Gene Expression Variability in Bilateral Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 196.	1.8	0
234	Gene Profiles in Breast Cancer. , 2019, , 351-361.		0

#	Article	IF	Citations
235	Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools. , 2008, , 15-32.		0
236	COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center. Vaccines, 2022, 10, 734.	2.1	0